Premium
A comparison study of prabotulinumtoxinA vs onabotulinumtoxinA in myostatin‐deficient mice with muscle hypertrophy
Author(s) -
Bak Dongho,
Choi Mi Ji,
Lee Esther,
Kwon TaeRin,
Kim Jong Hwan,
Nam SangHyun,
Kim KyoungYun,
Ahn Seung Won,
Mun SeogKyun,
Na Jungtae,
Kim Beom Joon
Publication year - 2019
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.13151
Subject(s) - myostatin , muscle hypertrophy , denervation , sciatic nerve , medicine , hindlimb , endocrinology , haematoxylin , skeletal muscle , muscle atrophy , atrophy , neuromuscular junction , acetylcholine , chemistry , biology , immunohistochemistry , neuroscience
Botulinum toxin A (Bo NT ‐A) is used clinically for various muscle disorders and acts by preventing the release of the neurotransmitter acetylcholine into the synapse space. Here, we compared the efficacy of prabotulinumtoxinA ( PRA ) and onabotulinumtoxinA ( ONA ) for the reduction in hypertrophy in myostatin‐deficient ( Mstn −/− ) mice. Two different Bo NT ‐A products (2.5, 10 and 25 U/kg) were injected to paralyse the hindlimb for 2 months, after which sciatic nerve conduction study, 3D micro‐ CT , haematoxylin and eosin (H&E) and dystrophin staining were conducted. Administration of Bo NT ‐A products induced denervation‐mediated atrophy and alleviated muscle hypertrophy generated in Mstn −/− mice. The present study revealed that each Bo NT ‐A regulates skeletal muscle size, myofibre number and myofibre diameter in Mstn −/− mice. The potential applicability of Bo NT ‐A for the treatment of rare muscle hypertrophic diseases was demonstrated. Compared with ONA , PRA had a comparable ability to act in the local area.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom